Literature DB >> 20597685

A TrkB Antibody Agonist Promotes Plasticity after Cervical Spinal Cord Injury in Adult Rats.

Karim Fouad1, Romana Vavrek1, Seongeun Cho1,2.   

Abstract

After spinal cord injury (SCI) in mammals, there is only limited repair and, consequently, only moderate recovery. One mechanism frequently discussed to be involved in this recovery is plasticity (i.e., adaptations in spared neuronal circuitries). In the current study, we tested the effect of an intrathecal application of the TrkB agonist antibody, 29D7, on plasticity after cervical SCI in adult rats. Treatment with 29D7 for 4 weeks resulted in an ∼50% increase in collateral sprouting of severed corticospinal tract fibers above the lesion compared to the control group and enhanced branching in the gray matter rostral to the injury. Growth-associated protein 43 immunoreactivity in the spinal cord rostral to the level of the injury as well as contralateral to the lesion was also increased. These indications of enhanced plasticity by 29D7 were paralleled by improved performances of the mildly affected paw, as assessed by Montoya and tray reaching tasks. The reaching behaviors of the paw ipsilateral to the side of severe injury to the cortico- and rubrospinal tract were not altered by the treatment. The present study suggests that 29D7 may be a potential candidate to promote plasticity and functional recovery, especially after moderate SCI. Future studies confirming these results, along with a potential combinatory therapy including rehabilitative training, will be needed to evaluate the clinical value of such a treatment.

Entities:  

Keywords:  BDNF; reaching; recovery; repair; sprouting

Mesh:

Substances:

Year:  2021        PMID: 20597685     DOI: 10.1089/neu.2009.1116

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  7 in total

1.  Melatonin prevents blood vessel loss and neurological impairment induced by spinal cord injury in rats.

Authors:  Yingli Jing; Fan Bai; Hui Chen; Hao Dong
Journal:  J Spinal Cord Med       Date:  2016-10-13       Impact factor: 1.985

Review 2.  Plasticity after spinal cord injury: relevance to recovery and approaches to facilitate it.

Authors:  Stephen M Onifer; George M Smith; Karim Fouad
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

3.  Promotion of corticospinal tract growth by KLF6 requires an injury stimulus and occurs within four weeks of treatment.

Authors:  Audra A Kramer; Greta M Olson; Advaita Chakraborty; Murray G Blackmore
Journal:  Exp Neurol       Date:  2021-02-14       Impact factor: 5.330

4.  Long-term viral brain-derived neurotrophic factor delivery promotes spasticity in rats with a cervical spinal cord hemisection.

Authors:  Karim Fouad; David J Bennett; Romana Vavrek; Armin Blesch
Journal:  Front Neurol       Date:  2013-11-19       Impact factor: 4.003

5.  Integrated printed BDNF/collagen/chitosan scaffolds with low temperature extrusion 3D printer accelerated neural regeneration after spinal cord injury.

Authors:  Xiao-Yin Liu; Chong Chen; Hai-Huan Xu; Yu-Sheng Zhang; Lin Zhong; Nan Hu; Xiao-Li Jia; You-Wei Wang; Kun-Hong Zhong; Chang Liu; Xu Zhu; Dong Ming; Xiao-Hong Li
Journal:  Regen Biomater       Date:  2021-08-12

6.  A Single Domain Shark Antibody Targeting the Transferrin Receptor 1 Delivers a TrkB Agonist Antibody to the Brain and Provides Full Neuroprotection in a Mouse Model of Parkinson's Disease.

Authors:  Emily Clarke; Pawel Stocki; Elizabeth H Sinclair; Aziz Gauhar; Edward J R Fletcher; Alicja Krawczun-Rygmaczewska; Susan Duty; Frank S Walsh; Patrick Doherty; Julia Lynn Rutkowski
Journal:  Pharmaceutics       Date:  2022-06-24       Impact factor: 6.525

7.  TrkB agonist antibody pretreatment enhances neuronal survival and long-term sensory motor function following hypoxic ischemic injury in neonatal rats.

Authors:  Gab Seok Kim; Seongeun Cho; James W Nelson; Gregory J Zipfel; Byung Hee Han
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.